- Home
- FLYW vs NRIX Comparison
FLYW vs NRIX Comparison
Compare FLYW & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- NRIX
- Stock Information
- Founded
- FLYW 2009
- NRIX 2009
- Country
- FLYW United States
- NRIX United States
- Employees
- FLYW N/A
- NRIX N/A
- Industry
- FLYW Computer Software: Prepackaged Software
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- FLYW Technology
- NRIX Health Care
- Exchange
- FLYW Nasdaq
- NRIX Nasdaq
- Market Cap
- FLYW 1.1B
- NRIX 1.1B
- IPO Year
- FLYW 2021
- NRIX 2020
- Fundamental
- Price
- FLYW $8.88
- NRIX $10.24
- Analyst Decision
- FLYW Buy
- NRIX Strong Buy
- Analyst Count
- FLYW 15
- NRIX 18
- Target Price
- FLYW $19.00
- NRIX $30.39
- AVG Volume (30 Days)
- FLYW 2.7M
- NRIX 1.3M
- Earning Date
- FLYW 05-06-2025
- NRIX 04-08-2025
- Dividend Yield
- FLYW N/A
- NRIX N/A
- EPS Growth
- FLYW N/A
- NRIX N/A
- EPS
- FLYW 0.02
- NRIX N/A
- Revenue
- FLYW $492,144,000.00
- NRIX $56,417,000.00
- Revenue This Year
- FLYW $13.82
- NRIX $12.84
- Revenue Next Year
- FLYW $16.21
- NRIX N/A
- P/E Ratio
- FLYW $378.45
- NRIX N/A
- Revenue Growth
- FLYW 22.09
- NRIX N/A
- 52 Week Low
- FLYW $8.20
- NRIX $8.18
- 52 Week High
- FLYW $23.40
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- FLYW 34.62
- NRIX 39.72
- Support Level
- FLYW $8.43
- NRIX $9.23
- Resistance Level
- FLYW $9.25
- NRIX $10.17
- Average True Range (ATR)
- FLYW 0.53
- NRIX 1.04
- MACD
- FLYW 0.18
- NRIX 0.15
- Stochastic Oscillator
- FLYW 37.26
- NRIX 53.51
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.